Rxsight, Inc. Stock Price, News & Analysis

RxSight, Inc. announced it will report its third-quarter financial results on November 10, 2021, after market close. The management will discuss the results in a conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the call via live webcast or by phone. RxSight focuses on innovative ophthalmic devices, specifically the Light Adjustable Lens system, which enhances visual acuity after cataract surgery. The product features ActivShield technology for UV protection.

RxSight, Inc. reported a strong second quarter in 2021 with revenues of $4.9 million, an 81% increase compared to the same period last year. Key drivers included the sale of 25 Light Delivery Devices and 1,825 Light Adjustable Lenses. The company received FDA approval for its updated Light Adjustable Lens with ActivShield technology, enhancing patient compliance. Operating expenses rose 57% to $13.1 million, primarily due to increased staffing. The net loss narrowed to $(13.5) million, compared to $(17.0) million in Q2 2020. Cash on hand was $61.7 million as of June 30, 2021.

RxSight, Inc. (NASDAQ: RXST) has rescheduled its second quarter 2021 financial results announcement to September 9, 2021, after market close, in respect of the Rosh Hashanah holiday. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET that same day, open to investors via a live and archived webcast. RxSight specializes in ophthalmic devices, offering the first customizable intraocular lens technology aimed at enhancing post-cataract surgery visual acuity, now featuring ActivShield™ technology for added UV protection.

RxSight, Inc. (NASDAQ: RXST) will participate in the virtual Wells Fargo Healthcare Conference on September 10, 2021, at 12:00 PM ET. Investors can access a live and archived webcast via the Investors section of the company's website. RxSight focuses on enhancing patients' vision post-cataract surgery with its Light Adjustable Lens system, the first of its kind that allows customization for improved visual acuity. The system now includes ActivShield technology for UV protection, further innovating ophthalmic treatments.

RxSight, Inc. announced it will disclose its Q2 2021 financial results after market close on September 7, 2021. The management will engage in a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Interested investors can access both live and archived webcasts of the call via RxSight's investor portal. This announcement precedes the release of financial performance metrics and operational updates for their innovative Light Adjustable Lens system.

RxSight, Inc. (NASDAQ: RXST) announced the appointment of Steve Everly as Vice President of U.S. Sales on August 17, 2021. Everly will lead the expansion of the company's sales organization, focusing on increasing physician adoption of the Light Adjustable Lens system equipped with ActivShield™ technology. With extensive experience in the ophthalmic field, including roles at Johnson & Johnson Vision and Abbott Laboratories, his expertise is expected to drive momentum in RxSight's sales. The company aims to enhance patient care post-cataract surgery through its innovative technologies.

RxSight, Inc., an ophthalmic medical device company, announced the addition of three new members to its Board of Directors effective August 3, 2021, following its IPO. New board members include Robert Palmisano, Robert Warner, and Julie Andrews, who bring extensive experience in commercial operations and finance. Concurrently, four longstanding board members resigned. RxSight aims to enhance patient vision post-cataract surgery with its innovative Light Adjustable Lens technology. The company expresses optimism regarding its future growth and transformation in the cataract surgery market.

RxSight, Inc. has completed its initial public offering (IPO) of 7,350,000 shares of common stock at $16.00 per share, generating approximately $132 million in gross proceeds. The offering includes the underwriters’ option to purchase an additional 898,594 shares, bringing the total to 8,248,594 shares sold. The shares started trading on Nasdaq under the symbol RXST on July 30, 2021. RxSight specializes in ophthalmic medical devices, particularly the innovative Light Adjustable Lens system designed to enhance patients' vision post-cataract surgery.

RxSight, an ophthalmic medical device company, has priced its initial public offering at $16.00 per share, raising approximately $117.6 million from the sale of 7,350,000 shares. The offering is set to close on August 3, 2021, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 1,102,500 shares. Trading on the Nasdaq will commence on July 30, 2021, under the ticker symbol RXST. This IPO marks a significant step for RxSight, as it aims to enhance the experience of patients post-cataract surgery.